DTIL
Precision BioSciences, Inc.
There isn't enough reported data to score DTIL yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DTIL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
DTIL's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
DTIL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $7.23 | -10% |
| Current | 24x | $8.04 | — |
| Fair | 31x | $10.17 | +26% |
| Expensive | 35x | $11.52 | +43% |
Historical ranges are pointers, not guarantees.
DTIL's PE is 24x, but its earnings don't support one, so it isn't a reliable read right now.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over DTIL in the historical PE scenario, which offers more potential upside but is not a forecast.
DTIL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect DTIL's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
DTIL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.33 | +$9.59 |
| Q2 2026 | -$1.23 | +$8.44 |
| Q1 2026 | -$2.10 | +$0.77 |
| Q4 2025 | -$3.56 | -442% |
| Q3 2025 | -$9.26 | -5888% |
| Q2 2025 | -$9.67 | -3219% |
| Q1 2025 | -$2.87 | +$4.49 |
| Q4 2024 | $1.04 | +$17.00 |
DTIL has returned to profit: it earned $0.33 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over DTIL on earnings, with more consistent year-over-year improvement.
DTIL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $10.8M | +37272% |
| Q4 2025 | $34.2M | +5261% |
| Q3 2025 | $13K | -98% |
| Q2 2025 | $18K | -100% |
| Q1 2025 | $29K | -100% |
| Q4 2024 | $638K | -91% |
| Q3 2024 | $576K | -96% |
| Q2 2024 | $49.9M | +152% |
DTIL's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -84% | +76165 points |
| Q4 2025 | 37% | +3931 points |
| Q3 2025 | -158977% | -155283 points |
| Q2 2025 | -121539% | -121587 points |
| Q1 2025 | -76248% | -76225 points |
| Q4 2024 | -3894% | -3683 points |
| Q3 2024 | -3694% | -3599 points |
| Q2 2024 | 48% | +109 points |
DTIL's operating margin was −84% last quarter, up 76165 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over DTIL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over DTIL on profitability, with a higher operating margin.
DTIL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.1M | +$138K |
| Q2 2026 | -$13.4M | +$6.8M |
| Q1 2026 | -$12M | +$7.2M |
| Q4 2025 | -$11.3M | +$7.5M |
| Q3 2025 | -$15.3M | -$9.3M |
| Q2 2025 | -$20.3M | -$5.4M |
| Q1 2025 | -$19.1M | -$49K |
| Q4 2024 | -$18.8M | -$10.4M |
DTIL has burned cash in almost every quarter: −$52M over the past year, against −$73M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over DTIL on cash generation, producing positive trailing cash flow while its opponent burns cash.
DTIL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.1% | +1.6M shares |
| 1 year | +148% | +16.4M shares |
| 3 years | +642% | +23.7M shares |
| 5 years | +1472% | +25.7M shares |
DTIL has 27M diluted shares, up 148% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over DTIL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
DTIL Net Leverage
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
DTIL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 55.4 | Neutral |
DTIL's weekly RSI is 54 (neutral) and its Stochastic is 55 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
DTIL PE vs Healthcare Sector
| Metric | DTIL | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 5.8% below |
| PE % | 17 | 29 | 12 pts below |
DTIL is trading at 24x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over DTIL on valuation relative to its sector.
DTIL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% above |
| 20 week MA | $7.47 | 7.6% above |
| 50 week MA | $6.35 | 27% above |
| 100 week MA | $5.75 | 40% above |
| 200 week MA | $10.3 | 22% below |
DTIL has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
DTIL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $421.5 | $280.5 | -33% |
| 2021 | $280.5 | $254.1 | -9.4% |
| 2022 | $254.1 | $30.3 | -88% |
| 2023 | $30.3 | $11.0 | -64% |
| 2024 | $11.0 | $4.65 | -58% |
| 2025 | $4.65 | $4.23 | -9% |
| 2026 YTD | $4.23 | $8.04 | +90% |
DTIL has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.